Bence C, Hofman V, Chamorey E, et al. - In patients with metastatic melanoma, researchers ascertained if the presence and the characteristics of pretreatment CD8+ tumor-infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker. Among 51 patients treated with ICIs and 54 patients treated with other treatment options (non-ICIs), the relationship of PD-L1 expression ≥ 5% of tumor cells combined with TILs features (CD8, CD28, Ki67) with the overall survival (OS), was evaluated. According to this retrospective study, PD-L1 positivity was noted in 33% and 39% of primary melanomas and matched metastases, with poor concordance, however, between the primary and matched metastatic site. There was no significant association between PD-L1 expression and CD8+TILs profile analyzed as single markers and OS or response to immunotherapy. Findings suggested that the pretreatment combination of PD-L1 expression with CD8+TILs level can help determine OS and predict clinical response of patients with metastatic melanoma if treated with immunotherapy or other treatment regimens.